KAICO Ltd. logo — Changing the World with Silkworms

KAICO Ltd.

Changing the World with Silkworms

Founded 2018 Japan Japan 10 employees Series B Total: $1.45B Biotechnology, Pharmaceutical

General Information

Company Name KAICO Ltd.
Founded Year 2018
Location Japan Japan +1
Employees 10
Industries Biotechnology, Pharmaceutical
Funding Stage Series B
Social

Get notified when KAICO Ltd. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About KAICO Ltd.

KAICO Ltd., founded in 2018, is a pioneering Japanese biotechnology startup that leverages its proprietary silkworm-baculovirus expression system to develop and produce recombinant proteins. By utilizing silkworms as bioreactors, KAICO offers a scalable and speedy solution for protein production, bypassing the need for traditional bio tanks.

The company's innovation centers around the development of oral vaccines for humans and animals, aiming to transform global health and increase livestock productivity. Oral vaccines present significant advantages, such as eliminating the need for syringes, medical personnel, and cold-chain logistics. This approach positions KAICO to potentially revolutionize healthcare access worldwide.

Recently, KAICO secured a ¥540.00M Series B investment on 01 April 2025, highlighting investor confidence in its transformative potential within the Biotechnology and Pharmaceutical industries.

Taxonomy: Recombinant Proteins, Silkworm-Baculovirus Expression System, Bioreactor, Scalable Production, Rapid Production, Oral Vaccines, Public Health, Animal Health, Livestock Productivity, Cold-chain Independence, Non-injectable Vaccines, Biopharmaceuticals, Diagnostic Drug Production

Services & Products

Protein Expression Service
Custom Protein Expression Trial Services
Veterinary and Human Vaccine Development
Research Reagents and Supplements

Target Customers

Pharmaceutical Companies Biotechnology Researchers Veterinary Health Organizations Human Healthcare Providers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• - 01 Apr 2025
Series A •••••• 4
Investor Investor Investor
•••• ••••
01 Jan 2024
Late Vc •••••• - 01 Dec 2021
Series A •••••• - 01 May 2020
Series A •••••• - 01 Dec 2019

View All 6 Funding Rounds

KAICO Ltd. Alternatives & Competitors

View All Alternatives
KAICO Ltd. vs

Streamlining protein therapeutics development

14 employees
KAICO Ltd. vs

Using rice as bioreactor to produce animal-free recombinant human albumin (OsrHSA)

19 employees
Biotechnology, Health Care
KAICO Ltd. vs

A Sundew company

Convertible Note
2-10 employees
Agriculture, Biotechnology

FAQ About KAICO Ltd.

Changing the World with Silkworms
KAICO Ltd. was founded in 2018.
KAICO Ltd. is headquartered in Japan.
KAICO Ltd. operates in the following industries: Biotechnology, Pharmaceutical.
KAICO Ltd. has approximately 10 employees.
KAICO Ltd. has completed 6 funding rounds, raising a total of $1.45B. The latest funding stage is Series B.
KAICO Ltd. offers: Protein Expression Service, Custom Protein Expression Trial Services, Veterinary and Human Vaccine Development, Research Reagents and Supplements.
Top alternatives and competitors to KAICO Ltd. include Pelican Expression Technology®, Wuhan Healthgen Biotechnology Corp., Microsynbiotix, Ltd., ORF Genetics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
KAICO Ltd. and Pelican Expression Technology® are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors KAICO Ltd. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy